Senators Want Public Input on Expensive Breakthrough Drugs

by Admin | January 28, 2016 3:50 pm

January 28, 2016—The Senate Finance Committee’s senior Democrat and a senior Republican member want to hear from the healthcare and patient communities about the negative financial and health impacts of highly expensive breakthrough drugs such as Gilead Sciences’ Sovaldi and Harvoni hepatitis C treatments.

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1]. Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:

Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2016/01/senators-want-public-input-on-expensive-breakthrough-drugs/